Alzamend Neuro (NASDAQ:ALZN) Vs. JANX, KRON, AKRO, CPRX, SLN, KDNY, ZGNX, KZR, PRLD, and DYN
Should you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Janux Therapeutics (JANX), Kronos Bio (KRON), Akero Therapeutics (AKRO), Catalyst Pharmaceuticals (CPRX), Silence Therapeutics (SLN), Chinook Therapeutics (KDNY), Zogenix (ZGNX), Kezar Life Sciences (KZR), Prelude Therapeutics (PRLD), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical preparations" industry.
Alzamend Neuro vs.
Kronos Bio (NASDAQ:KRON) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, community ranking, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.
Kronos Bio received 5 more outperform votes than Alzamend Neuro when rated by MarketBeat users. However, 100.00% of users gave Alzamend Neuro an outperform vote while only 72.73% of users gave Kronos Bio an outperform vote.
68.3% of Kronos Bio shares are held by institutional investors. Comparatively, 0.3% of Alzamend Neuro shares are held by institutional investors. 31.2% of Kronos Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Alzamend Neuro's return on equity of 0.00% beat Kronos Bio's return on equity.
Kronos Bio currently has a consensus price target of $36.00, indicating a potential upside of 175.65%. Alzamend Neuro has a consensus price target of $11.50, indicating a potential upside of 437.38%. Given Alzamend Neuro's higher probable upside, analysts plainly believe Alzamend Neuro is more favorable than Kronos Bio.
In the previous week, Kronos Bio and Kronos Bio both had 4 articles in the media. Kronos Bio's average media sentiment score of 0.35 beat Alzamend Neuro's score of 0.00 indicating that Kronos Bio is being referred to more favorably in the media.
Summary
Kronos Bio and Alzamend Neuro tied by winning 4 of the 8 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alzamend Neuro (NASDAQ:ALZN) vs. Its Competitors
Alzamend Neuro Competitors List
